← All organizations
Highest phase reached
Phase 3
First clinical trial
Nov 1, 2005First marketed drug
Feb 28, 2023First NDA
Feb 28, 2023Last known activity
Feb 28, 2023
Acquired by Biogen-IDEC on Sep 26, 2023
Timeline
2000s
- Jun 1, 2002
Reata Pharmaceuticals, Inc.— Founded
2020s
- Feb 28, 2023
omaveloxolone— Marketing Organization
- Feb 28, 2023
omaveloxolone— NDA Organization
- Feb 28, 2023
omaveloxolone— NDA Secondary Org
- Sep 26, 2023
Biogen-IDEC— Acquired By
Drugs by trial phase (17 distinct, 48 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (11 own, 0 via acquisition)
Indications
Studied for
- Ataxia
- Brain Neoplasms
- Bronchiolitis
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Cataract
- Cerebellar Ataxia
- Connective Tissue Diseases
- Corneal Endothelial Cell Loss
- Coronavirus Infections
- Cryptogenic Organizing Pneumonia
- Dermatitis
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Familial Primary Pulmonary Hypertension
- Fibrosis
- Friedreich Ataxia
- Glioma
- Glomerulonephritis, IGA
- Glomerulosclerosis, Focal Segmental
- Hypertension
- Hypertension, Pulmonary
- Idiopathic Interstitial Pneumonias
- Idiopathic Pulmonary Fibrosis
- Inflammation
- Kidney Diseases
- Kidney Failure, Chronic
- Liver Diseases
- Lung Diseases
- Lung Diseases, Interstitial
- Lung Neoplasms
- Melanoma
- Meningeal Carcinomatosis
- Meningitis
- Mitochondrial Myopathies
- Muscular Diseases
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
- Nephritis, Hereditary
- Pancreatic Neoplasms
- Pneumonia
- Polycystic Kidney, Autosomal Dominant
- Polycystic Kidney Diseases
- Pulmonary Fibrosis
- Radiodermatitis
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Sarcoidosis
- Syndrome
Marketed drugs (1)
Recent trials (48)
- NCT03593499Lead sponsorN/A—
- NCT04702997Lead sponsorPhase 2Feb 9, 2021
- NCT04494646CollaboratorPhase 2/Phase 3Sep 8, 2020
- NCT03902002Lead sponsorPhase 1Jul 31, 2019
- NCT04008186Lead sponsorPhase 1Jun 14, 2019
- NCT03918447Lead sponsorPhase 3May 29, 2019
- NCT03931590Lead sponsorPhase 1Apr 11, 2019
- NCT03749447Lead sponsorPhase 3Mar 8, 2019
- NCT03664453Lead sponsorPhase 1Oct 31, 2018
- NCT03579030Lead sponsorPhase 1Jun 20, 2018
- NCT03366337Lead sponsorPhase 2Dec 26, 2017
- NCT03264079Lead sponsorPhase 1Oct 16, 2017
- NCT03068130Lead sponsorPhase 3Apr 18, 2017
- NCT03019185Lead sponsorPhase 2/Phase 3Mar 2, 2017
- NCT02666963Lead sponsorPhase 1Jan 1, 2017
Details
- Founded
- Irving, TX, US Jun 1, 2002
- First NDA
- Feb 28, 2023
- Last known activity
- Feb 28, 2023
Designations held
- Orphan drug
- Fast track
- Priority review